Clarithromycin Significantly Increases Linezolid Serum Concentrations

被引：28

作者：

Bolhuis, Mathieu S. ^{[1
]}

van Altena, Richard ^{[2
]}

Uges, Donald R. A. ^{[1
]}

van der Werf, Tjip S. ^{[3
]}

Kosterink, Jos G. W. ^{[1
]}

Alffenaar, Jan-Willem C. ^{[1
]}

机构：

[1] Univ Groningen, Dept Hosp & Clin Pharm, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

[2] Univ Groningen, TB Ctr Beatrixoord, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

[3] Univ Groningen, Dept Internal Med & Pulm Dis & TB, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2010年 / 54卷 / 12期

关键词：

MULTIDRUG-RESISTANT TUBERCULOSIS; IN-VITRO; MYCOBACTERIUM-TUBERCULOSIS; TOLERABILITY; EFFICACY; SAFETY;

D O I：

10.1128/AAC.00757-10

中图分类号：

Q93 [微生物学];

学科分类号：

071005 [微生物学];

摘要：

引用

页码：5418 / 5419

页数：2

共 11 条

[1]

In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs [J].

Alcalá, L ;

Ruiz-Serrano, MJ ;

Turégano, CPF ;

Garcia de Viedma, D ;

Díaz-Infantes, M ;

Marín-Arriaza, M ;

Bouza, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :416-417

[2]

Limited Sampling Strategies for Therapeutic Drug Monitoring of Linezolid in Patients With Multidrug-Resistant Tuberculosis [J].

Alffenaar, Jan-Willem C. ;

Kosterink, Jos G. W. ;

van Altena, Richard ;

van der Werf, Tjip S. ;

Uges, Donald R. A. ;

Proost, Johannes H. .

THERAPEUTIC DRUG MONITORING, 2010, 32 (01) :97-101

[3]

Role of P-glycoprotein inhibition for drug interactions:: Evidence from in vitro and pharmacoepidemiological studies [J].

Eberl, Sonja ;

Renner, Bertold ;

Neubert, Antje ;

Reisig, Mareike ;

Bachmakov, Iouri ;

Koenig, Joerg ;

Doerje, Frank ;

Muerdter, Thomas E. ;

Ackermann, Andreas ;

Dormann, Harald ;

Gassmann, Karl G. ;

Hahn, Eckhart G. ;

Zierhut, Stefanie ;

Brune, Kay ;

Fromm, Martin F. .

CLINICAL PHARMACOKINETICS, 2007, 46 (12) :1039-1049

[4]

Decreased serum linezolid levels in a critically ill patient receiving concomitant linezolid and rifampin [J].

Gebhart, Benjamin C. ;

Barker, Brian C. ;

Markewitz, Boaz A. .

PHARMACOTHERAPY, 2007, 27 (03) :476-479

[5]

HARMELINK IM, 2008, EUR J HOSP PHARM, V14, P5

[6]

Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis [J].

Koh, Won-Jung ;

Kwon, O. Jung ;

Gwak, Hyesun ;

Chung, Joo Won ;

Cho, Sang-Nae ;

Kim, Woo Sung ;

Shim, Tae Sun .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (02) :388-391

[7]

Efficacy and tolerability of daily-half dose linezolid in patients with intractable multidrug-resistant tuberculosis [J].

Park, I-Nae ;

Hong, Sang-Bum ;

Oh, Yeon-Mok ;

Kim, Mi-Na ;

Lim, Chae-Man ;

Lee, Sang Do ;

Koh, Younsuck ;

Kim, Woo Sung ;

Kim, Dong Soon ;

Kim, Won Dong ;

Shim, Tae Sun .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 58 (03) :701-704

[8]

In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis [J].

Rodríguez, JC ;

Ruiz, M ;

López, M ;

Royo, G .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (06) :464-467

[9]

Linezolid: a review of safety and tolerability [J].

Vinh, Donald C. ;

Rubinstein, Ethan .

JOURNAL OF INFECTION, 2009, 59 :S59-S74

[10]

Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB) - a report of ten cases [J].

von der Lippe, B ;

Sandven, P ;

Brubakk, O .

JOURNAL OF INFECTION, 2006, 52 (02) :92-96

← 1 2 →